Hong et al found that the low expression of LRRC17 was a risk factor for fracture in postmenopausal women.38 However, there is little published data on LRRC17 function in cancer.39, 40 Ochoa et al41, 42 suggested that LYPD6B enhanced the sensitivity of (α3)3(β4)2 nicotinic acetylcholine (ACh) receptors to ACh. Here, LRRC17 is linked to cancer.